CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (Nasdaq: DYAX) announced today that Trubion Pharmaceuticals, Inc. has exercised an option to expand its existing research agreement, which covers protein therapeutics and diagnostics discovery. In addition to the ongoing multiple-target funded research project, Dyax will now transfer its proprietary phage library to Trubion’s facility for use in identifying therapeutic leads to additional targets, further enabling Trubion’s ability to rapidly design and develop product candidates for a range of disease targets. Additional terms of the expanded agreement were not disclosed.
